Tutti gli studi
Iscrizione su invitoOSSERVAZIONALE

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

This important study is designed for adult men in the UK living with haemophilia B. It's a long-term follow-up for those who previously took part in earlier studies (CSL222_2001 or CSL222_3001) where they received a gene therapy treatment called etranacogene dezaparvovec. The main purpose is to see how safe the treatment remains over many years and how effective it continues to be in managing their haemophilia B. By carefully monitoring participants, researchers hope to gain a better understanding of the lasting effects of this innovative treatment, which could ultimately help improve future care for people with this condition.

A colpo d'occhio

Stato
Iscrizione su invito
Sponsor
CSL Behring
Obiettivo di iscrizione
56
Inizio
30 Ago 2023
Completamento stimato
23 Mar 2035

Di cosa tratta questo studio?

This study is a follow-up for adult men with haemophilia B who have already received a special gene therapy. Haemophilia B is a lifelong bleeding disorder where your blood doesn't clot properly due to a missing or faulty ‘Factor IX’ protein. Gene therapy like etranacogene dezaparvovec aims to provide instructions to your body to make this missing protein, potentially reducing bleeding episodes.

This particular study isn't offering new treatment; instead, it's looking at the long-term effects for people who have already had this gene therapy. Researchers want to understand if the treatment continues to be safe over many years and if it keeps working effectively to help manage haemophilia B. This is really important because gene therapies are relatively new, and understanding their long-term impact helps doctors and scientists make informed decisions about their wider use.

By carefully checking on the health and progress of these participants, the study contributes valuable information. It helps build a bigger picture of how this treatment works in the real world, beyond the initial trials. This knowledge is crucial for advancing our understanding of haemophilia B and developing even better therapies in the future.

Punti chiave

  • This is a long-term follow-up study for men with haemophilia B.
  • Participants have already received a gene therapy called etranacogene dezaparvovec.
  • The study aims to understand the long-term safety and effectiveness of the treatment.
  • No new medication is given; it involves regular monitoring and health checks.
  • Your participation helps improve future care for haemophilia B patients.

Chi può essere idoneo?

To be considered for this study, you must be an adult male who previously participated in one of the original treatment trials for etranacogene dezaparvovec – specifically, study CSL222_2001 or study CSL222_3001.

Additionally, you must have either fully completed your participation in one of those earlier studies, or at least five years must have passed since you received the etranacogene dezaparvovec gene therapy in one of those trials.

There are no other specific reasons listed that would prevent you from joining this follow-up study, provided you meet the criteria above.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I am an adult male (aged 18 or over).
  2. I was previously treated with etranacogene dezaparvovec (CSL222) in study CSL222_2001 or CSL222_3001.
  3. I completed my participation in one of those earlier studies.
  4. OR at least 5 years have passed since I received the CSL222 treatment.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part, you'll be regularly monitored by a medical team. This will involve scheduled visits to the clinic where you'll have various health checks. These typically include blood tests to measure your Factor IX levels and check your general health, physical examinations, and questions about any bleeding episodes or your overall well-being. You won't be receiving new medication as part of this study; it's purely for observation. The total duration of your participation will depend on how long ago you received the gene therapy, as the study aims to track participants for many years after their initial treatment.

Rischi e benefici potenziali

Participating in this study offers a potential benefit of ongoing, close medical supervision of your health, particularly regarding your haemophilia B and the effects of the gene therapy you received. You would also be contributing valuable information that could help others living with haemophilia B in the future. As you have already received the treatment, the direct risks from the treatment itself are not new, but any long-term monitoring study involves regular clinic visits, which can be time-consuming, and blood tests, which carry minimal risks like bruising. You are free to withdraw from the study at any time without needing to give a reason, and this will not affect your usual medical care.

Locations (28)

  • 10-15 Phoenix Childrens Hospital
    Codice postale verificato
    Phoenix, Stati Uniti
  • 10-14 Arkansas Children's Hospital - Pharmacology
    Codice postale verificato
    Little Rock, Stati Uniti
  • 10-22 Orthopaedic Institute for Children
    Codice postale verificato
    Los Angeles, Stati Uniti
  • 10-21 Children's Hospital of Los Angeles
    Codice postale verificato
    Los Angeles, Stati Uniti
  • 10-63 UC Davis Medical Center
    Codice postale verificato
    Sacramento, Stati Uniti
  • 10-12 University of California, San Diego (UCSD)
    Codice postale verificato
    San Diego, Stati Uniti
  • 10-25 University of Colorado Denver
    Codice postale verificato
    Aurora, Stati Uniti
  • 10-19 University of South Florida
    Codice postale verificato
    Tampa, Stati Uniti
  • 10-10 University of Michigan Medical Center
    Codice postale verificato
    Ann Arbor, Stati Uniti
  • 10-16 University of North Carolina at Chapel Hill
    Codice postale verificato
    Chapel Hill, United States
  • 10-18 Oregon Health & Science University
    Codice postale verificato
    Portland, Stati Uniti
  • 10-20 Vanderbilt University Medical Center
    Codice postale verificato
    Nashville, Stati Uniti

Domande comuni

What is haemophilia B?

Haemophilia B is an inherited bleeding disorder where your blood doesn't clot properly due to a missing or faulty Factor IX protein, leading to prolonged bleeding.

What is etranacogene dezaparvovec?

It's a gene therapy treatment that aims to help your body produce the missing Factor IX protein, which can reduce bleeding episodes in people with haemophilia B.

Am I receiving new treatment in this study?

No, this study is a follow-up. You won't receive new treatment; it's for monitoring those who previously had the gene therapy.

Quanto tempo dovrò rimanere nello studio?

The study aims for long-term follow-up; the duration for you will depend on when you received your initial gene therapy treatment in the parent studies.

What is the purpose of this long-term study?

The main purpose is to understand the long-term safety and effectiveness of etranacogene dezaparvovec gene therapy for men with haemophilia B.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Long-term Follow-up Study of Male Adults With Hemophilia B P…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.